Impact of upfront Xpert testing on time to treatment initiation for multidrug-resistant TB

Int J Tuberc Lung Dis. 2021 Jul 1;25(7):584-586. doi: 10.5588/ijtld.21.0092.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibiotics, Antitubercular* / pharmacology
  • Antibiotics, Antitubercular* / therapeutic use
  • Drug Resistance, Bacterial
  • Humans
  • Mycobacterium tuberculosis*
  • Rifampin
  • Time-to-Treatment
  • Tuberculosis, Multidrug-Resistant* / diagnosis
  • Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

  • Antibiotics, Antitubercular
  • Rifampin